Patents Examined by Robert D. Budens
  • Immunostimulatory bacterial cell wall traction
    Patent number: 5759554
    Abstract: The present invention relates to an immunotherapeutic agent that is effective in treating a variety of diseases in animals and humans. More particularly, the present invention is a preparation of a modified mycobacterial cell wall extract that does not contain oil, that is capable of stimulating the immune system of an animal or human in such a way as to cause the body to neutralize, abort or eliminate infections, tumors and other disorders.
    Type: Grant
    Filed: December 9, 1994
    Date of Patent: June 2, 1998
    Assignee: Vetrepharm, Inc.
    Inventors: Stanley J. Alkemade, Thomas C. Buckley, Graeme McRae
  • Human monoclonal anti-HIV-I-antibodies
    Patent number: 5753503
    Abstract: The invention is directed to human monoclonal antibodies specific for the gp41 envelope protein of human immunodeficiency virus type 1 (HIV-1). Specifically disclosed are the human monoclonal antibodies produced by the cell lines 3D6 having ECACC Accession No. 87110301, 24G3 having ECACC Accession No. 90091702 and 25C2 having ECACC Accession No. 80120601.
    Type: Grant
    Filed: December 1, 1994
    Date of Patent: May 19, 1998
    Assignee: Hermann W. D. Katinger
    Inventors: Hermann W. D. Katinger, Ruediger von Baehr, Alois A. Jungbauer, Tomas Porstmann, Franz J. Steindl, Roland Grunow
  • Human monoclonal antibodies to cytomegalovirus
    Patent number: 5750106
    Abstract: The present invention is directed to the human monoclonal antibody designated SDZ MSL 109 produced by the hybridoma cell line designated EV 2-7 having NCACC Accession No. 85 100 803. The human monoclonal antibody is specific for cytomegalovirus (CMV) and is useful as a therapeutic agent for treating CMV infections.
    Type: Grant
    Filed: June 25, 1993
    Date of Patent: May 12, 1998
    Assignee: Novartis AG
    Inventor: Lars G. Ostberg
  • gC1q receptor, HIV-1 gp120 region binding thereto, and related peptides and targeting antibodies
    Patent number: 5739306
    Abstract: Disclosed are immunogens and peptides based on the binding site of gC1q-R for HIV-1 gp120, and immunogens and peptides based on the binding site of HIV-1 gp120 for gC1q-R. The sequence of the gC1q-R binding site for gp120 is shown in SEQ ID NO.: 2. The sequence of the HIV-1 gp120 binding site for gC1q-R is shown in SEQ ID NO.: 3. Also disclosed are antibodies and binding molecules to all such immunogens and peptides, and inducing the endogenous production of such antibodies.
    Type: Grant
    Filed: September 9, 1996
    Date of Patent: April 14, 1998
    Assignee: Tanox Biosystems, Inc.
    Inventors: Michael S.C. Fung, Bill N.C. Sun, Cecily R.Y. Sun, Young Woo Kim, Liming Yu
  • gC1q receptor, HIV-1 gp120 region binding thereto, and related peptides and targeting antibodies
    Patent number: 5731428
    Abstract: Disclosed are immunogens and peptides based on the binding site of gClq-R for HIV-1 gp120, and immunogens and peptides based on the binding site of HIV-1 gp120 for gClq-R. The sequence of the gClq-R binding site for gp120 is shown in SEQ ID NO.: 2. The sequence of the HIV-1 gp120 binding site for gClq-R is shown in SEQ ID NO.: 3. Also disclosed are antibodies and binding molecules to all such immunogens and peptides, and inducing the endogenous production of such antibodies.
    Type: Grant
    Filed: September 6, 1996
    Date of Patent: March 24, 1998
    Assignee: Tanux Biosystems, Inc.
    Inventors: Michael S. C. Fung, Bill N. C. Sun, Cecily R. Y. Sun, Young Woo Kim, Liming Yu
  • Immuno-potentiating systems for preparation of immunogenic materials
    Patent number: 5726292
    Abstract: The invention is directed to improved immunopotentiating systems for preparation of immunogenic materials. More particularly, the invention is directed to immunogenic compositions containing a protein, polypeptide, or peptide, a hydrophobic anchor, and a proteosome. The immunogenic compositions are suitable for use as therapeutic agents and vaccines.
    Type: Grant
    Filed: October 29, 1993
    Date of Patent: March 10, 1998
    Inventor: George H. Lowell
  • Methods of treating HIV infection using antibodies to the U2 small nuclear ribonuclear protein
    Patent number: 5707626
    Abstract: Therapeutic strategies for the treatment of immunoinfective cluster virus infections in humans involving the use of antibodies or fragments thereof which are characteristic of autoantibodies produced by patients affected with systemic rheumatic disorders and cross-react with epitopes on an immunoinfective cluster virus. Additional therapeutic strategies include the use U1 RNA or fragments thereof to treat said viral infections.
    Type: Grant
    Filed: August 28, 1996
    Date of Patent: January 13, 1998
    Assignee: University of Southern California
    Inventors: Angeline Douvas, Yoshi Takehana, Glenn Ehresmann
  • Monoclonal antibodies specific for HIV and the hybridomas for production thereof
    Patent number: 5695927
    Abstract: Human monoclonal antibodies which belong to the IgG1 subclass and are specific for HIV are described. The monoclonal antibodies have potential for use in the diagnosis, prevention and therapy of HIV infection.
    Type: Grant
    Filed: July 1, 1994
    Date of Patent: December 9, 1997
    Assignees: The University of Arizona, Department of Internal Medicine, Section of Hematology and Oncology, Teijin Limited
    Inventors: Yasuhiko Masuho, Toru Sugano, Yoh-ichi Matsumoto, Takashi Kawamura, Evan Hersh, Eskild Petersen, Douglas Lake
  • GC1q receptor, HIV-1 gp120 region binding thereto, and related peptides and targeting antibodies
    Patent number: 5691447
    Abstract: Disclosed are immunogens and peptides based on the binding site of gC1q-R for HIV-1 gp120, and immunogens and peptides based on the binding site of HIV-1 gp120 for gC1q-R. The sequence of the gC1q-R binding site for gp120 is shown in SEQ ID NO.: 2. The sequence of the HIV-1 gp120 binding site for gC1q-R is shown in SEQ ID NO.: 3. Also disclosed are antibodies and binding molecules to all such immunogens and peptides, and inducing the endogenous production of such antibodies.
    Type: Grant
    Filed: March 24, 1995
    Date of Patent: November 25, 1997
    Assignee: Tanox Biosystems, Inc.
    Inventors: Michael S. C. Fung, Bill N. C. Sun, Cecily R. Y. Sun, Young Woo Kim, Liming Yu
  • Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
    Patent number: 5681718
    Abstract: Methods for enhancing the production of tissue plasminogen activator (TPA) in cell culture are disclosed. The methods involve culturing TPA-producing cells in growth media supplemented with an alkanoic acid or salt thereof at a concentration which enhances TPA production. The most preferred methods utilize butyric acid or sodium butyrate at a concentration of between 0.5 mM and 2.5 mM.
    Type: Grant
    Filed: December 14, 1994
    Date of Patent: October 28, 1997
    Assignee: Celltech Limited
    Inventor: Raymond Paul Field
  • Use of GM-CSF as a vaccine adjuvant
    Patent number: 5679356
    Abstract: The present invention is a method for enhancing the immune response of a mammal to a vaccine by administering to such a mammal an effective amount of GM-CSF in conjunction with a vaccine. The present invention further provides for pharmaceutical compositions containing an effective amount of GM-CSF and a vaccine. Kits containing GM-CSF and a vaccine are also disclosed.
    Type: Grant
    Filed: January 5, 1995
    Date of Patent: October 21, 1997
    Assignee: Schering Corporation
    Inventors: Eric M. Bonnem, Imtiaz A. Chaudry, Elliot Stupak
  • Bovine herpesvirus type 1 deletion mutants and vaccines
    Patent number: 5676951
    Abstract: A deletion mutant of bovine herpesvirus type 1 which has a deletion in the glycoprotein gE-gene and which may further have a deletion in the thymidine kinase gene and/or the glycoprotein gI-gene, or have an insertion of a heterologous gene is disclosed. Recombinant nucleic acids which encode the gE-gene or a part thereof are also disclosed, in addition to vaccines and a method of treatment.
    Type: Grant
    Filed: December 6, 1993
    Date of Patent: October 14, 1997
    Assignee: Stichting Centraal Diergeneeskundig Instituut
    Inventors: Franciscus Antonius Maria Rijsewijk, Johannes Theodorus van Oirschot, Roger Kamiel Maes
  • Method for isolation of unclipped HIV envelope protein
    Patent number: 5674984
    Abstract: Methods for producing and isolating unclipped HIV env proteins are provided. According to the methods, an antibody directed to an HIV epitope spanning the env clip site is used to selectively separate unclipped HIV env protein from clipped env protein.
    Type: Grant
    Filed: April 11, 1994
    Date of Patent: October 7, 1997
    Assignee: Genentech, Inc.
    Inventors: Phillip W. Berman, Brian M. Fendly, Timothy J. Gregory, Florian M. Wurm
  • Monoclonal antibodies reactive with cachectin
    Patent number: 5658803
    Abstract: Cell lines are provided that produce improved neutralizing monoclonal antibodies reactive with human cachectin. The antibodies have various therapeutic and diagnostic uses.
    Type: Grant
    Filed: December 6, 1994
    Date of Patent: August 19, 1997
    Assignee: Chiron Corporation
    Inventor: George Kuo
  • Polypeptides of feline T-cell lymphotrophic lentivirus
    Patent number: 5656732
    Abstract: Purified polypeptides of Feline Immunodeficiency Virus (FIV) are disclosed. The polypeptides of the invention include p10, p15, p26, gp40, gp100 and gp130.
    Type: Grant
    Filed: September 15, 1994
    Date of Patent: August 12, 1997
    Assignee: IDEXX Laboratories, Inc.
    Inventors: Philip R. Andersen, Thomas P. O'Connor, Quentin J. Tonelli
  • Eimeria antigenic composition which elicits antibodies against avian coccidiosis
    Patent number: 5656485
    Abstract: This invention relates to novel recombinant antigenic proteins of avian coccidiosis, and fragments thereof containing antigenic determinants, and to the genes that encode the antigenic peptides. This invention also relates to vaccines made using the novel antigenic proteins of avian coccidiosis and to methods of immunizing chickens against avian coccidia.
    Type: Grant
    Filed: August 2, 1996
    Date of Patent: August 12, 1997
    Assignee: BTG USA Inc.
    Inventors: James W. Jacobson, Robert L. Strausberg, Susan D. Wilson, Sharon H. Pope, Susan Lee Strausberg, Michael D. Ruff, Patricia C. Augustine, Harry D. Danforth
  • Human anti-TNF antibodies
    Patent number: 5654407
    Abstract: Human monoclonal antibodies (mAbs) which bind to human TNF.alpha. are disclosed. Autoantibodies of both the IgM and IgG isotypes are disclosed. A preferred human monoclonal antibody is known as B5 (F78-1A10-B5 mAb) and it binds to recombinant human TNF.alpha. (rhTNF.alpha.) in ELISA format with a titer comparable to three high affinity neutralizing mouse mAbs. It also binds to cell surface TNF.alpha. and prevents TNF.alpha. secretion by human monocyte cell lines.
    Type: Grant
    Filed: May 5, 1995
    Date of Patent: August 5, 1997
    Assignee: Bayer Corporation
    Inventors: Petra Boyle, Gayle D. Wetzel, Kenneth J. Lembach
  • gC1q receptor, HIV-1 gp120 region binding thereto, and related peptides and targeting antibodies
    Patent number: 5652333
    Abstract: Disclosed are immunogens and peptides based on the binding site of gC1q-R for HIV-1 gp120 and immunogens and peptides based on the binding site of HIV-1 gp120 for gC1q-R. The sequence of the gC1q-R binding site for gp120 is shown in SEQ ID NO.: 2. The sequence of the HIV-1 gp120 binding site for gC1q-R is shown in SEQ ID NO.: 3. Also disclosed are antibodies and binding molecules to all such immunogens and peptides, and inducing the endogenous production of such antibodies.
    Type: Grant
    Filed: September 6, 1996
    Date of Patent: July 29, 1997
    Assignee: Tanox Biosystems, Inc.
    Inventors: Michael S. C. Fung, Bill N. C. Sun, Cecily R. Y. Sun, Young Woo Kim, Liming Yu
  • Human neutralizing monoclonal antibodies to human immunodeficiency virus
    Patent number: 5652138
    Abstract: The present invention describes human monoclonal antibodies which immunoreact with and neutralize human immunodeficiency virus (HIV). Also disclosed are immunotherapeutic and diagnostic methods of using the monoclonal antibodies, as well as cell line for producing the monoclonal antibodies.
    Type: Grant
    Filed: July 18, 1994
    Date of Patent: July 29, 1997
    Assignee: The Scripps Research Institute
    Inventors: Dennis R. Burton, Carlos F. Barbas, Richard A. Lerner
  • Therapeutic antibody based fusion proteins
    Patent number: 5645835
    Abstract: The present invention relates to methods of providing a targeted, amplified antitumor immune response using antibody-based fusion proteins. More specifically, the invention relates to the use of antibody-based fusion proteins comprising an immunoglobulin portion capable of binding to a tumor antigen linked to a biologically active lymphokine. The immunoglobulin portion targets the fusion protein to the site of the tumor cells and the lymphokine portion stimulates the proliferation of immune T cells at the site of the tumor cells, thereby amplifying the anti-tumor immune response. In preferred embodiments of the invention, the immunoglobulin portion of the fusion protein is derived from the L6 monoclonal antibody and/or the lymphokine is interleukin-2.
    Type: Grant
    Filed: May 23, 1994
    Date of Patent: July 8, 1997
    Assignee: Oncogen
    Inventors: Henry Perry Fell, Jr., Margit Ann Gayle